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Steatohepatitis (SH) is an intermediate stage of fatty liver disease
and is one of the most common causes of chronic liver disease
worldwide that may progress to cirrhosis and liver cancer. SH
encompasses alcoholic and non-alcoholic steatohepatitis, the lat-
ter being of particular concern as it is associated with obesity and
insulin resistance and has become a major cause of liver trans-
plantation. The molecular mechanisms governing the transition
from steatosis to SH are not fully understood. Here we discuss
emerging data indicating that the acid sphingomyelinase
(ASMase), a speciﬁc mechanism of ceramide generation, is
required for the activation of key pathways that regulate steato-
sis, ﬁbrosis and lipotoxicity, including endoplasmic reticulum
stress, autophagy and lysosomal membrane permeabilization.
Moreover, ASMase modulates alterations of the methionine cycle
and phosphatidylcholine homeostasis, two crucial events
involved in SH that regulate methylation reactions, antioxidant
defence and membrane integrity. These new ﬁndings suggestJournal of Hepatology 20
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Fatty liver disease covers a spectrum of disorders that begins
with steatosis that can progress to steatohepatitis, ultimately cul-
minating in hepatocellular carcinoma (HCC). Steatohepatitis is
characterized by steatosis, hepatocellular death, inﬂammation
and ﬁbrosis and encompasses alcoholic (ASH) and non-alcoholic
steatohepatitis (NASH) [1]. ASH is a disease with a high-mortality
[2]. NASH, which has a high prevalence in Western countries
(3–16%) due to its association with obesity and insulin resistance
(I/R), is a global health concern and a major cause of liver
transplantation [3]. Despite recent progress, the mechanisms
underlying the transition from steatosis to ASH/NASH are still
poorly understood. In line with the ‘‘two-hit’’ hypothesis [4],
the accumulation of lipids in the cytoplasm of hepatocytes,
mostly in form of free fatty acids (FA) and triglycerides (TG), is
considered a ﬁrst step and a sensitizing factor to secondary hits
that promote ASH/NASH.
Although the predominant view of the two-hit hypothesis
postulates that fat quantity determines disease progression,
recent ﬁndings have shown that the type of fat rather than its
amount sensitizes the fatty liver to second hits promoting steato-
hepatitis [5,6]. Nutritional and genetic models of hepatic steatosis
with selective types of fat demonstrated that cholesterol, partic-
ularly mitochondrial cholesterol (mChol), rather than TG/FA
accumulation, sensitized hepatocytes to TNF/Fas-mediated ste-
atohepatitis. Subsequent studies conﬁrmed this concept [7–9],
and paved the way for translational lipidomic studies in patients,
describing the association of a dysregulated cholesterol metabo-
lism with NASH [10,11]. Other studies delineated the association
of NASH with changes in hepatic lipid composition [12,13].15 vol. 62 j 219–233
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Fig. 1. ASMase in steatohepatitis: One target, multiple pathways. ASMase
becomes activated in liver samples of patients and experimental models of ASH
and NASH. Recent evidence shows that ASMase is required for endoplasmic
reticulum (ER) stress, autophagy and lysosomal membrane permeabilization
(LMP) in ASH/NASH, which in turn mediates insulin resistance (I/R), lipogenesis,
ﬁbrosis and regulates steatosis. LMP is a novel pathway of lipotoxicity that cross-
talks with mitochondria to induce apoptosis/necrosis. Moreover, ASMase activa-
tion depletes hepatic S-adenosyl-L-methionine (SAM) and phosphatidylcholine
(PC), which are key intermediates in liver physiology via methylation of multiple
substrates (DNA, proteins and lipids), maintenance of antioxidant and GSH
defence, and membrane integrity. Thus, ASMase contributes to liver steatosis,
liver injury, inﬂammation and ﬁbrosis, characteristic of ASH/NASH. ASMase
targeting may be a novel target of potential relevance for ASH/NASH by disabling
multiple pathogenic pathways.
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Currently there is no approved therapy for ASH/NASH and the
existing treatments are inefﬁcient. Uncovering the molecular
mechanisms and interplay of key metabolic players may lead to
the design of novel therapeutic combinations. Acid sphingomye-
linase (ASMase), which generates ceramide by sphingomyelin
(SM) hydrolysis, mediates TNF/Fas-induced hepatocellular apop-
tosis and promotes liver ﬁbrogenesis [14–16]. Recent evidence
demonstrates that ASMase regulates key mechanisms involved
in steatosis, ﬁbrosis and lipotoxicity, including endoplasmic retic-
ulum (ER) stress, autophagy and lysosomal membrane permeabi-
lization (LMP), which contribute to ASH and NASH (Fig. 1)
[6,17,18]. A disturbed methionine metabolism, exempliﬁed by
decreased S-adenosyl-L-methionine (SAM, also abbreviated as
SAMe or AdoMet) and/or increased S-adenosylhomocysteine
(SAH) and homocysteine (Hcy) levels, and phosphatidylcholine
(PC) depletion control key liver functions and have been
described in experimental models of steatohepatitis and in
patients [19–26]. Moreover, emerging data link ASMase activa-
tion with modulation of SAM and PC homeostasis, suggesting that
targeting ASMase and restoring methionine metabolism and PC
levels may be a promising strategy for the treatment of ASH/
NASH.
Key Points
• ASMase is activated during ASH and NASH and is 
required for the activation of key molecular pathways 
mediating ASH/NASH, such as ER stress, autophagy 
and lysosomal membrane permeabilization (LMP)
• Persistent ER stress is a principal pathway that 
mediates insulin resistance, lipogenesis and steatosis. 
Autophagy has been described as a novel pathway 
causing lipid degradation, hence preventing steatosis, 
and has emerged as a mediator of liver fibrosis. LMP is 
a central process mediating lipotoxicity by a cross-talk 
between mitochondria and lysosomes
• Decreased S-adenosyl-L-methionine (SAM) and 
phosphatidylcholine (PC) levels are key factors 
contributing to ASH/NASH by altering methylation 
reactions, antioxidant defences and membrane 
integrity. Their repletion was shown to be protective in 
experimental models but their impact in humans with 
ASH/NASH remains to be further confirmed
• Emerging evidence indicates a reciprocal regulation 
between ASMase, decreased SAM and perhaps 
also with low PC content. In particular, ASMase 
activation leads to SAM depletion and a decreased 
SAM/ S-adenosylhomocysteine (SAH) ratio further 
activates ASMase. In addition to the altered methionine 
metabolism, ASMase is activated by oxidative stress 
and inflammatory cytokines
• Therapies targeting ASMase, in association with the 
replenishment of SAM and PC levels, may be a novel 
approach for the treatment of ASH/NASH, as they may 
have the additional advantage of inhibiting ER stress, 
autophagy and LMP220 Journal of Hepatology 201Pathways regulating lipid metabolism, ﬁbrosis and
lipotoxicity in steatohepatitis
Endoplasmic reticulum stress
The ER controls protein synthesis and folding. Misfolded proteins
cause ER stress and trigger the unfolded protein response (UPR), a
complex signalling network, aimed to restore protein homeosta-
sis by reducing protein synthesis and expanding protein folding.
The UPR comprises three transducers, inositol requiring (IRE) 1a,
PKR-like ER kinase (PERK), and activating transcription factor
(ATF) 6a, which activate a wide range of downstream targets
[27–29]. Glucose-regulated protein 78 (GRP78, also known as
BiP) is the master regulator, controlling activation of the UPR.
Upon physiological conditions GRP78 binds these transducers
and prevents their activation; however, accumulation of
misfolded proteins sequesters GRP78 releasing IRE1a, PERK,
and ATF6a to initiate the UPR.5 vol. 62 j 219–233
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ER stress and the UPR become activated during metabolic
alterations in the liver and their persistent activation contributes
to ASH/NASH by triggering apoptosis, steatosis and I/R [28–32].
In addition to activating XBP-1, IRE1a recruits TNFR-associated
receptor 2 leading to JNK activation. Bak and Bax are pro-apopto-
tic Bcl2 family members, which interact with the IRE1a pathway
and mediate, in part, ER stress-induced apoptosis. Pro-caspase-12
also associates with activated IRE1a, allowing its proteolytic
cleavage to active caspase-12. CHOP is an important mediator
of ER stress-induced apoptosis, as it activates pro-apoptotic genes
including the death receptor 5 (DR5), BCL2-like protein 11 (BIM),
and Tribbles homolog 3 (TRIB3). Additionally, ER stress-mediated
Ca2+ release recruits and activates the mitochondrial apoptotic
pathway [33]. Moreover, c-Jun N-terminal kinase (JNK) activation
by ER stress is a critical mediator of I/R by interfering with insulin
signalling, due to insulin receptor serine phosphorylation. ER
stress inhibition by chemical chaperones restores insulin signal-
ling and alleviates I/R [34]. Finally, an emerging role of ER stress
in liver ﬁbrogenesis involves the XBP-1 and IRE1a arms of the
UPR [35]. While activation of the IRE1a/XBP-1 pathway triggers
autophagy and the Nrf2-dependent antioxidant response in a
p38-dependentmanner, the persistent activation of this particular
arm of the UPR promotes liver ﬁbrosis via autophagy regulation.
These ﬁndings argue that targeting speciﬁcally the IRE1a pathway
in hepatic stellate cells (HSC) may be a novel antiﬁbrotic therapy.
ER stress also promotes lipogenesis and hepatic steatosis by
activating the ER transcription factors SREBP-1c and SREBP-2,
which control synthesis of FA and cholesterol, respectively. Phos-
phorylation of eIF2a and activation of the PERK pathway pro-
motes lipogenesis by decreasing INSIG-1 protein translation, a
retention protein of the SREBP cleavage-activating protein
(SCAP)/SREBP complex into the ER, resulting in the activation of
SREBP-1c. UPR, induced by alcohol feeding and increased Hcy
levels, activates SREBP-1c to induce lipogenic gene expression
[31,36]. ER stress triggered by thapsigargin or tunicamycin in
hepatocytes caused SREBP-1c activation, the induction of the tar-
get genes fatty acid synthase (FASN), acetyl-CoA carboxylase 1
(ACACA) and hepatic steatosis [37]. GRP78 overexpression inhib-
its ER stress-induced SREBP-1c activation and reduces hepatic
steatosis [38]. Overall, ER stress is a key mechanism contributing
to apoptosis, steatosis and ﬁbrosis.
Autophagy
Autophagy is a complex and highly regulated proteolytic path-
way, involved in the turnover of organelles and cellular debris,
which are targeted to lysosomes for degradation [39]. During
autophagy, cytoplasmic materials (e.g., organelles or protein
aggregates) are sequestered in a double membrane structure,
the phagophore (also known as isolation membrane), that length-
ens to create an autophagosome, which then fuses with lyso-
somes to form an autolysosome where its content is degraded.
Activated during nutrient starvation, autophagy is considered as
a protective mechanism by channelling cellular components for
energy supply. Autophagy disruption is involved in the progres-
sion of many liver diseases, including ASH/NASH [39]. Besides
the dual role of autophagy in cell death, promoting survival or
death, depending on the context, recent evidence described a
novel role of autophagy in lipid metabolism and hepatic steatosis,
called lipophagy [40]. Until recently, the breakdown of TG and
lipid droplets in hepatocytes had been thought to occur throughJournal of Hepatology 201the activation of cytosolic lipases. However, pharmacological or
genetic inhibition of autophagy in hepatocytes results in hepatic
steatosis. Moreover, mice with liver-speciﬁc deletion of Atg7
(Atg7Dhep), a key protein that regulates autophagosome forma-
tion, exhibited defective autophagy and increased TG and choles-
terol storage underlying hepatic steatosis [40]. Autophagy
induction by the liver-speciﬁc overexpression of Atg7 in ob/ob
mice improves the metabolic state and reduces steatosis [41].
This new concept fostered the view that impaired autophagy
causes hepatic steatosis. Furthermore, by providing FA for the
mitochondrial b-oxidation and ATP production, lipophagy regu-
lates not only lipid stores but also cellular energy homeostasis.
While attractive, the link between impaired autophagy and hepa-
tic steatosis needs to be further conﬁrmed [42]. For instance,
Atg7Dhep mice, fed a HFD, have a reduced hepatic lipid content
[43]. Moreover, mice with liver-speciﬁc deletion of FIP200, a core
subunit of the Atg1 complex, are protected from starvation and
HFD-induced hepatic steatosis [44]. The view of autophagy as a
lipogenic mechanism is also supported by the role of fasting in
both processes. Fasting triggers autophagy and it is also known
to cause hepatic steatosis. Thus, the role of autophagy in lipid
metabolism and hepatic steatosis is complex and may be regu-
lated by several factors, such as genetic background, experimen-
tal conditions or aging.
In addition to regulating lipid metabolism, autophagy pro-
motes ﬁbrogenesis by activating HSCs to a myoﬁbroblastic phe-
notype that leads to the generation of collagen and degradation
of matrix architecture. The most characteristic feature of hepatic
stellate cells in normal liver is the presence of perinuclear mem-
brane-bound droplets ﬁlled with retinyl esters. Recent ﬁndings
have established that the loss of lipid droplets during HSC activa-
tion results from increased autophagic vacuoles and autophagic
ﬂux [45,46]. Pharmacologic or genetic autophagy inhibition
attenuated HSC activation and ﬁbrogenesis. Importantly, mice
with a genetic deletion of Atg7 in HSCs have reduced ﬁbrosis fol-
lowing sustained liver injury [47]. The link between lipophagy
and HSC activation implies that autophagy increases energy pro-
duction by liberating FA from retinyl esters to serve as an energy
source for HSCs.
Lysosomal membrane permeabilization
Lysosomes are membrane bound organelles, containing special-
ized hydrolytic enzymes, used for digestion and removal of pro-
tein and organelles. In addition to their central role in the
turnover of macromolecules, lysosomes play a critical role in cell
death regulation [48,49]. A key step, engaging lysosomes in cell
death, is the permeabilization of lysosomes, which allows the
release of lysosomal content for cell death initiation. Regulation
of lysosomal membrane permeabilization (LMP) is thus an
important mechanism modulating the participation of lysosomes
in cell death pathways, and LMP has emerged as a promising new
target of relevance in cancer cell biology and therapy. LMP is
caused by a wide range of stimuli, including ROS, saturated FA,
sphingosine or cell death effectors such as Bax. LMP releases lyso-
some contents to the cytosol, including cathepsins (e.g. cathepsin
B, CTSB), which in turn target mitochondria, leading to apoptosis.
Cathepsin B can cause caspase-independent cell death or recruit
mitochondria by BH3-interacting domain death agonist (BID)
cleavage. Of relevance for steatohepatitis, palmitic acid (PA), one of
themost abundant saturated FA in western diets, causes lipotoxicity5 vol. 62 j 219–233 221
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by multifactorial mechanisms, including an ER-mitochondrial
cross-talk [50]. Accordingly, it has been described that PA induces
LMP in hepatocytes, causing the release of cathepsin B, preceding
mitochondrial dysfunction and cytochrome c release [51]. Conse-
quently, cathepsin B antagonism, by pharmacological inhibition
or genetic silencing, protected hepatocytes against PA-mediated
lipoapoptosis. Thus, LMP is an important pathway promoting sat-
urated FA-mediated lipotoxicity. As discussed below, ASMase is
required for LMP and PA-mediated hepatocellular death.
Methionine metabolism and phosphatidylcholine
homeostasis in steatohepatitis
Reduced SAM levels and hyperhomocysteinemia
Methionine is primarily metabolized in the liver. Cirrhosis delays
plasma clearance of methionine and alcohol alters hepaticBetaine
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222 Journal of Hepatology 201methionine metabolism [20]. Methionine metabolism begins with
its conversion to SAM by methionine adenosyltransferase I/III
(MAT-I/III), the products of the MAT1A a gene expressed almost
exclusively in the liver [19,52]. SAM is essential in liver physiol-
ogy as it functions as methyl donor and glutathione (GSH) pre-
cursor (Fig. 2). The methylation of acceptors (e.g., DNA,
proteins, and lipids), catalysed by methyl transferases, converts
SAM to SAH, which is hydrolysed to Hcy and adenosine by SAH
hydrolase (SAHH). Methylation of Hcy by methionine synthase
(MS) or betaine homocysteine methyltransferase (BHMT), using
5-methyltetrahydrofolate (5MTHF) or betaine as methyl donors,
respectively, yields methionine, closing the cycle. The 5MTHF-
dependent MS reaction links the folate cycle to the methionine
cycle. SAM is catabolized by the glycine N-methyltransferase
(GNMT) in a reaction that catalyses the methylation of glycine
to form sarcosine. Besides remethylation to methionine, Hcy
can be converted to cystathionine by cystathionine-b synthaseBetaine
H
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(CBS), which is processed to cysteine that can be used for protein
synthesis or GSH formation.
SAM is a versatile metabolite that promotes survival in hepa-
tocytes and apoptosis in liver cancer cells [53]. It has been
reported that alcohol decreases SAM levels in rats, mice and
humans, leading to increased SAH levels [20,54–57]. The conse-
quent alteration in the SAM/SAH ratio impairs hepatocellular
functions, including methylation reactions and compromises
the antioxidant defence due to GSH depletion, which sensitizes
cells to TNF and oxidant-induced hepatocellular injury [19,58].
The mechanisms, whereby alcohol depletes SAM, involve MATI/
III inactivation by posttranslational modiﬁcations [59], and
impaired Hcy remethylation due to methionine synthase inhibi-
tion. Additionally, alcohol-induced perturbation of the methio-
nine metabolism leads to increased Hcy levels [28,31]. The rise
in Hcy is associated with alcohol-induced ER stress, which in turn
contributes to steatosis and cell death. However, as discussed
below, Hcy-induced ER stress requires ASMase.
SAM is synthesized in the cytosol and in nuclei but a signiﬁ-
cant bulk (about 30%) is found in mitochondria (mSAM), where
it plays a critical role in the methylation of mitochondrial compo-
nents, in the synthesis of ubiquinone [57,60,61] and in the main-
tenance of membrane dynamics needed for the transport of
mitochondrial GSH (mGSH) [62–64]. Chronic alcohol intake
inhibits the transport of mSAM, leading to mSAM depletion inde-
pendently of the changes on membrane ﬂuidity induced by alco-
hol [65].
To explore the role of hepatic SAM in liver disease, Mato and
colleagues generated MAT1A/ mice [66]. MAT1A/ mice dis-
played reduced hepatic SAM and GSH levels. Although histologi-
cally normal, 3-month-old MAT1A/ mice have hepatic
hyperplasia and develop fatty liver on a choline deﬁcient (CD)
diet. Additionally, these mice develop spontaneous NASH and
HCC at a later age. These ﬁndings established a pivotal role for
SAM in liver function, and demonstrate that MAT1A deletion
determines the progression of NASH to HCC. Consistent with
the role of BMHT in maintaining Hcy and SAM homeostasis,
BMHT/ mice exhibit hyperhomocysteinemia and a decreased
liver SAM/SAH ratio together with lower PC and SM content
and betaine accumulation [67]. BMHT/ mice develop liver stea-
tosis at an early age that progresses to HCC. These results indicate
that BHMT has an important role in Hcy and methionine homeo-
stasis, thus regulating susceptibility to NASH and HCC. Moreover,
GNMT/ mice, which have increased SAM levels, develop liver
steatosis, ﬁbrosis, and HCC, presumably due to aberrant DNA
and histone methylation and abnormal PC/PE ratio [68]. The
excess SAM content in GNMT/ mice reroutes phosphatidyletha-
nolamine (PE) towards PC and TG synthesis via the PEMT path-
way (see below) [69], while SAM depletion by nicotinamide
administration or feeding of a methionine deﬁcient (MD) diet
prevents steatosis and ﬁbrosis in GNMT/ mice [69,70]. The ﬁnd-
ings in the MAT1A/ mice (with low hepatic SAM) and in the
GNMT/ mice (with high hepatic SAM) highlight the importance
of appropriate levels of SAM in liver physiology.
Interestingly, recent ﬁndings have shown that GNMT regu-
lates liver cholesterol by stabilizing NPC2 (Niemann-Pick disease
type C2), an endolysosomal protein involved in intracellular cho-
lesterol trafﬁcking [71]. Accordingly, GNMT/ mice exhibit
decreased NPC2 expression and increased hepatic free choles-
terol. Given the role of cholesterol in ASH/NASH and the rele-
vance of mChol in cell death and HCC [5,7,8,10,12,72], it isJournal of Hepatology 201conceivable that, in addition to the alteration of DNA and histone
methylation and abnormal PC/PE ratio, the accumulation of
mChol may contribute to the phenotype of GNMT/ mice.
Whether or not the protection by nicotinamide administration
or MD feeding in GNMT/ mice [69,70] regulates NPC2 expres-
sion and hepatic free cholesterol homeostasis remains to be
established.
Reduced phosphatidylcholine levels
The glycerolipids PC and PE are the most abundant phospholipid
species in eukaryotic bilayers and are essential for the structure
and function of cell membranes. PC and PE are synthesized de
novo from choline and ethanolamine, respectively, in the two
branches of the Kennedy pathway, based on the formation of
high-energy intermediates, CDP-choline and CDP-ethanolamine,
which are often referred to as the CDP-choline and CDP-ethanol-
amine pathway, respectively [73]. During PC synthesis, ﬂux
through the CDP-choline pathway is controlled by CTP: phospho-
choline cytidylyltransferase (CCT). CCT exists in two isoforms,
CCTa and CCTb, of which CCTa is the predominant isoform
present in liver [74]. Hepatic PC can also be produced via
the phosphatidylethanolamine N-methyltransferase (PEMT) that
catalyses the methylation of PE to PC using SAM as methyl donor
[75]. Thus, PEMT links the methionine cycle to PC homeostasis
(Fig. 3). Although the methylation of PE via PEMT is the only
pathway for conversion of PE to PC, it accounts for 20–30% of
hepatic PC synthesis [76]. However, this pathway is essential
for the generation of speciﬁc molecular species of PC. In addition
to the CDP-choline pathway, another important source of hepatic
PC comes from lipoproteins [77].
PC homeostasis is an important factor for ASH/NASH. Patients
with hepatic steatosis have 25% less PC in the liver compared to
normal subjects [12]. In addition, a functional polymorphism
(V175M substitution) within the PEMT gene has been associated
with NASH in humans [78,79]. This polymorphism decreases the
speciﬁc activity of PEMT, suggesting that impaired hepatic PC
biosynthesis might play a key role in human NASH. PEMT dele-
tion impairs VLDL secretion, causing hepatic steatosis [80,81].
To explore the role of PC in NASH, Li et al. fed PEMT/ mice a
CD diet [22]. In contrast to wild type littermates fed a CD diet,
PEMT/ mice developed NASH, exhibiting liver failure, panlobu-
lar macrovesicular steatosis, hepatocellular ballooning, Mallory’s
hyaline, and panacinar inﬂammation. Liver injury resulted from a
loss of membrane integrity, caused by a decreased PC/PE ratio
[22]. Liver samples from patients with NASH also exhibited
decreased PC/PE ratio. Interestingly, increased PC levels and sub-
sequent higher PC/PE ratio in the hepatic ER of obese mice have
been shown to disrupt Ca2+ homeostasis by inhibiting the
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump, which
triggers ER stress and impaired glucose tolerance [30]. Consider-
ing the contrast between MAT1A/ and GNMT/ mice regarding
SAM levels and PC/PE ratio, it is clear that both abnormally high
and low levels of SAM and PC/PE may contribute to ASH/NASH.
Liver-speciﬁc CCTa (LCCTa)/ mice have impaired apoB-100
secretion and exhibit decreased hepatic PC levels and increased
TG accumulation on a regular diet [82]. Interestingly, LCCTa/
mice display increased MAT1A and BHMT expression, likely as
a compensatory mechanism to meet methylation demand in
the context of PC limitation [83]. Feeding LCCTa/ mice a high
fat diet (HFD) leads to severe NASH within one week, with liver5 vol. 62 j 219–233 223
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injury, ballooning and lobular and portal inﬂammation [25].
LCCTa/ mice also exhibit increased hepatic diacylglycerol
(DAG) and ceramide levels. As the CDP-choline pathway utilizes
DAG to produce PC (Fig. 3), the increase in DAG levels observed
in LCCTa/ mice on HFD was due to impaired PC synthesis rather
than increased DAG biogenesis [25]. Although the source of
increased hepatic ceramide content was not addressed, PC con-
sumes ceramide for the synthesis of SM in the Golgi [84], suggesting
that the increased ceramide content may reﬂect the limitation in
SM synthesis due to low PC availability. In addition to the role of
PC in hepatic steatosis via regulation of VLDL secretion, a novel
link between the level of PC and steatosis has been described,
involving a non-canonical processing of SREBP. Low PC (or
decreased SAM) levels results in the proteolytic processing of
SREBP-1 in the ER followed by the nuclear translocation of
mature SREBP-1, stimulating lipogenesis [85]. This process is dis-
tinct from the classical pathway, which involves the SCAP-depen-
dent transfer of SREBPs from the ER to the Golgi when cholesterol
is limiting. By disrupting the localization of the Golgi-resident
SREBP-activating proteases SP1/SP2 and promoting their trafﬁck-
ing to the ER, low PC levels stimulate the ectopic proteolytic
cleavage of SREBP-1 in the ER, allowing the transcriptional
regulation of lipogenic enzymes (Fig. 3). While this process was
initially described in C. elegans and in hepatoma cells it was also
conﬁrmed in livers of LCCTa/ mice, which exhibit deﬁcient
PC biosynthesis but increased MAT1A expression [82,83]. The
activation of hepatic SREBP-1 in LCCTa/ mice paralleled the
upregulation of SCD1, an SREBP-1 target gene, and was
not observed for SREBP-2, indicating a selective process [85].
Intriguingly, MAT1A/ mice do not exhibit increased SREBP-1
levels (Lu and Mato, unpublished observations). Whether the
latter outcome indicates a differential role of low SAM in the
alternative processing of SREBP-1, or if a threshold for PC is required
for SREBP-1 activation, remains to be further investigated.
Impaired MAT and PEMT activity has been reported in liver
samples from patients with alcoholic cirrhosis [54]. Alcohol feed-
ing in baboons reduced the conversion of hepatic PE to PC, which
preceded the onset of ﬁbrosis [86]. Alcohol-fed mice showed a
decreased PC/PE ratio despite unchanged activity and expression
of PEMT [87]. This outcome may be due to the limitation of SAM
levels by alcohol intake, as betaine feeding or BHMT overexpres-
sion restored the decreased PC/PE upon alcohol feeding. Overall,
these ﬁndings underscore the relationship between methionine
metabolism and PC homeostasis and their impact on SH, and
show that phospholipid methylation in the liver is a major con-
sumer of SAM.Acid sphingomyelinase in steatohepatitis
Pathways of ceramide generation and its role in metabolism and
steatohepatitis
Ceramide is a critical component of membrane bilayers and in
addition regulates apoptosis, cellular senescence, stress response,
inﬂammation and metabolism [84,88–91]. Cells generate cera-
mide by several mechanisms. De novo synthesis occurs in the
ER via the condensation of serine and palmitoyl-CoA, catalysed
by serine palmitoyltransferase (SPT), and the subsequent acyla-
tion of sphingosine with fatty acyl chains of different lengths
by ceramide synthases (CerS), which exhibit speciﬁcity toJournal of Hepatology 201different fatty acids, giving rise to heterogeneous ceramide
species [92]. In addition to this de novo pathway, ceramide can
be produced by SM hydrolysis through activation of SMases, of
which the Mg2+-dependent, membrane-bound neutral NSMase,
with a pH optimum of 7.5, and ASMase, with a pH optimum of
4.8, (further classiﬁed as lysosomal and secretory ASMase)
mediate apoptosis and stress signalling [16,84,88,89].
The role of de novo ceramide synthesis in liver metabolism
and pathophysiology has been investigated primarily within
the context of hepatic I/R, which is closely associated with NASH
and obesity and is a major risk factor for dyslipidemia, hyper-
tension and cardiovascular diseases [90,91]. Studies using lard
oil infusions have suggested that, speciﬁcally saturated fatty
acids activate TLR-4 signalling through the adaptor protein
MyD88, leading to the activation of IjB kinase, upregulation of
de novo ceramide biosynthesis and ceramide-induced activation
of protein phosphatase 2A, which directly inhibits insulin signal-
ling at the level of protein kinase B (Akt) phosphorylation
[91,93]. In this model, TLR-4 receptor signalling and ceramide
synthesis are both critical for saturated fat-induced hepatic
insulin resistance. In contrast, unsaturated fat-induced insulin
resistance is not dependent on the TLR-4 receptor or ceramide
synthesis [93,94]. However, this model has been disputed by
recent ﬁndings, showing that both saturated and unsaturated
fatty acids induce hepatic insulin resistance independently of
TLR-4 signalling and ceramide de novo biosynthesis in vivo
through DAG accumulation and subsequent PKCe activation
[95]. Moreover, mice deleted for CerS2, which preferentially
synthesizes very long-chain ceramides (C22–C24), exhibit a
compensatory increase in levels of C16 and sphinganine in the
liver [96]. These changes in ceramide homeostasis translate into
increased rates of hepatocyte apoptosis and proliferation that
progress to the widespread formation of nodules of regenerative
hepatocellular hyperplasia in aged mice. Progressive hepato-
megaly and non-invasive hepatocellular carcinoma are also
observed from approximately 10 months of age [96]. The role
of de novo ceramide synthesis in the saturated fatty acid (e.g.
palmitic acid) mediated lipotoxicity in hepatocytes remains to
be established. While palmitic acid is a precursor of ceramide
synthesized in the ER, the link between palmitic acid, de novo
ceramide generation and ER stress in hepatotoxicity is contro-
versial and poorly understood. Our observations, however, indi-
cate that myristic acid potentiates palmitic acid-induced de novo
ceramide synthesis, ER stress and lipotoxicity in primary mouse
hepatocytes by a mechanism involving the N-myristoylation and
subsequent activation of dihydroceramide synthase (Martinez
et al., manuscript in preparation).
Information on the role of NSMase in steatohepatitis is scant
and limited to the study of FAN (factor associated with NSMase
activation). FAN/ mice fed a methionine and choline deﬁcient
(MCD) diet exhibit steatohepatitis, decreased PC/PE ratio and
increased ceramide generation, indicating that FAN is dispensable
in this model of NASH [97]. However, recent evidence demon-
strates that ASMase promotes ASH/NASH and that it regulates
key players in lipid metabolism.
ASMase promotes hepatocellular apoptosis, liver ﬁbrosis and ASH/
NASH
Several mechanisms can contribute to the activation of ASMase
in steatohepatitis. As an enzyme mediating stress response and5 vol. 62 j 219–233 225
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apoptosis, ASMase is activated by TNF, ROS and oxidative stress,
which are critical players in steatohepatitis (see below). The gen-
eration of ASMase/ mice has been a useful tool to study its role
in cellular stress, infection, and apoptosis [98–101]. ASMase deﬁ-
ciency models Niemann-Pick type A disease, a lysosomal storage
disease characterized by the accumulation of SM, cholesterol, and
glycosphingolipids in lysosomes of affected organs, particularly
brain and liver [102,101]. ASMase is expressed in almost every
cell type and is located mainly within the endosomal/lysosomal
compartment, although it has also been found in speciﬁc micro-
domains in the plasma membrane functioning as a signalling
platform for cell surface receptors (e.g. Fas) [103]. ASMase medi-
ates TNF-induced hepatocellular apoptosis and TNF/Gal-medi-
ated fulminant liver failure and Fas-induced lethal hepatitis
[14,104,105], involving the recruitment of mitochondria through
ganglioside GD3 generation, which elicits apoptosis by a dual
mechanism of ROS generation and NF-jB inhibition [106,107].
Moreover, Cu2+-induced hepatocellular apoptosis, characteristic
of Wilson’s disease, requires ASMase [108]. ASMase inhibition
with desipramine in rats with a mutation in the Atp7b gene, a
genetic model of Wilson’s disease, protects against Cu2+-induced
hepatocyte death and liver failure. In addition to its role in cell
death, ASMase regulates HSC activation and liver ﬁbrogenesis.
Selective stimulation of ASMase, but not NSMase, occurs
during the transdifferentiation of primary mouse HSCs to
myoﬁbroblast-like cells, coinciding with the processing of the
downstream effectors cathepsin B and D [15]. ASMase
antagonism blunted cathepsin B/D processing and prevented
the activation and proliferation of mouse and human HSCs. More-
over, it has been shown that amitriptyline, an ASMase inhibitor,
reduces established hepatic ﬁbrosis induced by CCl4 in mice
[109].
ASMase is implicated in alcoholic liver disease [110]. Alcohol
feeding activates ASMase and liver biopsies from patients with
acute alcoholic hepatitis exhibit increased ASMase mRNA levels
[6,111,112]. Moreover, ASMase/ mice are resistant to alcohol-
induced lipogenesis, macrosteatosis, mChol loading and subse-
quent LPS sensitization and concanavalin A-mediated liver injury
[6]. This inability of alcohol to stimulate mChol trafﬁcking was
due to the lack of StARD1 expression, a protein essential for the
regulation of cholesterol movement to the mitochondrial inner
membrane that is regulated by ER stress. Moreover, ASMase inhi-
bition with amitriptyline in wild type mice prevented alcohol-
induced steatosis, liver injury and LPS sensitization, without
compromising liver regeneration. Additionally, ASMase is overex-
pressed in adipose tissue of ob/ob mice, in mice fed an MCD diet,
and in liver and serum samples from patients with NASH
[15,113–115]. Moreover, ASMase deletion, superimposed on a
genetic background of LDL receptor deﬁciency (LDLr//ASM-
ase/), prevented diet-induced hyperglycemia and steatosis
[116]. These improvements in LDLr//ASMase/ mice were
associated with a paradoxical increase in hepatic ceramide levels
and de novo ceramide synthesis due to increased SPT expression.
These ﬁndings contrast with the effects of ASMase overexpres-
sion in diabetic db/db mice, which improves glucose metabolism
[117]. ASMase/ mice, fed a HFD, were resistant to HFD-induced
activation of lipogenic enzymes [17]. These ﬁndings translated
into resistance to HFD-mediated steatosis, with similar ﬁndings
observed when mice were fed a MCD diet. Furthermore, ASMase
inhibition with amitriptyline protected wild type mice against
HFD-induced steatosis, liver injury, inﬂammation and ﬁbrosis.226 Journal of Hepatology 201Collectively, these ﬁndings indicate that ASMase plays a critical
role in both ASH/NASH.
ASMase regulates ER stress
Consistent with the resistance to alcohol or HFD-induced lipo-
genesis and steatosis, ASMase deﬁciency prevented the expres-
sion of ER stress markers after alcohol or HFD feeding [6,17].
This outcome did not reﬂect an inherent defect of ASMase/
mice to sense ER stress, as tunicamycin induced the expression
of ER stress markers and led to increased TG levels, resulting in
steatosis [6]. This resistance to alcohol-mediated ER stress was
observed despite an increase in plasma Hcy to levels similar to
those found in alcohol-fed wild type littermates, regardless of
whether alcohol was administered orally or intragastrically,
suggesting that resistance to alcohol-induced ER stress in the
absence of ASMase is independent of hyperhomocysteinemia
(Baulies et al., unpublished observations) [6]. Consistent with
these ﬁndings, Boini et al. recently showed that ASMase abla-
tion prevented Hcy-induced glomerular injury in CBS+/ mice,
a genetic model of hyperhomocysteinemia and increased
plasma Hcy levels [118,119]. In this model, ASMase silencing
prevented Hcy-induced ceramide generation, indicating that
ASMase activation by Hcy is a major pathway of glomerular
ceramide generation. The ﬁndings in alcohol-fed ASMase/
mice (intragastrically or orally) are in line with data in mice
fed a chow diet supplemented with Hcy, which exhibited
increased plasma Hcy levels (3–7 fold) but no pathophysiologic
changes or ER stress [120]. Moreover, supplementing MCD diet
with Hcy attenuates MCD-induced hepatic UPR activation and
liver injury. These results suggest that Hcy at pathophysiological
concentrations plays a minor role in ER stress and steatosis and
that the associations between Hcy and UPR are not causally
related. HFD feeding increased the expression of ER stress
markers in livers of ASMase+/+ mice but not in ASMase/ mice
[17]. The requirement of ASMase for alcohol or HFD elicited ER
stress argues that ASMase-induced ceramide production per se
triggers ER stress. Treatment of hepatocytes with exogenous
ASMase, but not NSMase, caused ER stress by a mechanism
involving disruption of ER Ca2+ homeostasis [6], consistent with
the release of Ca2+ from the ER to the cytosol caused by cera-
mide [30,32,121], supporting the concept that aberrant lipid
composition in the ER regulates SERCA, and hence ER Ca2+
homeostasis and subsequent ER stress susceptibility. However,
whether ASMase activation modulates SERCA activity in the
ER, by perturbing ER membrane physical properties, remains
to be established. In support for an endolysosomal/ER relation-
ship, previous ﬁndings in Niemann Pick type C (NPC) disease
have shown that stimulation of ER Ca2+ release by SERCA to
the cytosol overcomes reduced lysosomal Ca2+ levels in NPC1/
cells, and corrects endocytic transport [122]. Lysosomal SM
accumulation through ASMase deﬁciency inhibits the activity
of a principle lysosomal Ca2+ channel (TRPML1) and blocks
lysosomal Ca2+-dependent membrane trafﬁcking [123].
Since NPC1 disease is characterized by increased accumulation
of endolysosomal cholesterol and sphingolipids, it is conceivable
that NPC1, whose physiological role is to participate in
the transfer of cholesterol from lysosomes to the ER, may
contribute to the transfer of ceramide from endolysosomes
to the ER to mediate the effect of ASMase as an ER stress
trigger.5 vol. 62 j 219–233
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ASMase regulates autophagy: The differential role of autophagy in
steatosis and ﬁbrosis
Mouse coronary arterial smooth muscle cells from ASMase/
mice exhibit a defect in the fusion of autophagosomes with lyso-
somes due to impaired lysosomal function [18]. Knockdown of
ASMase suppressed the induction of autophagy in leukemia HL-
60 cells induced by amino acid deprivation [124] and ASMase is
required for the upregulation of Atg5 expression and autophagy
induction in HepG2 cells [125]. ASMase can regulate autophagy
by several mechanisms. Decreased SM in lysosomes by ASMase
can regulate the TRPLM1/lysosomal Ca2+/dynein axis. Dynein is
a multi-subunit microtubule motor protein complex, involved
in the trafﬁcking of autophagosomes with lysosomes to form
autolysosomes that translates to an increased number of auto-
phagosomes [126–128]. Ceramide, an ASMase intermediate, par-
ticipates in lysosome fusion to cell plasma membranes,
endosomes, phagosomes and other organelles, and it is known
to regulate cytoskeleton and microtubule assembly [129–132].
Moreover, ceramide can directly interact with LC3I, which may
facilitate the targeting of lysosomes to autophagosomes [133].
In line with these ﬁndings, hepatocytes from ASMase/ mice
exhibit defective autophagic ﬂux and, intriguingly, this outcome
occurs despite resistance to HFD-induced steatosis [17]. This dis-
sociation between autophagy and hepatic steatosis, as described
above, is consistent with the ﬁnding that autophagy disruption
by shRNA-mediated suppression of Atg7 failed to cause hepatic
steatosis in lean mice [41]. These ﬁndings demonstrate that the
role of autophagy in lipid metabolism and steatosis is more com-
plex than thought and may be modulated by other factors. ER
stress and autophagy are mutually regulated and defective
autophagy triggers ER stress [41]. Accordingly, suppression of
autophagy with chloroquine/brefeldin triggered ER stress in pri-
mary hepatocytes of ASMase+/+ mice but not ASMase/ mice,
indicating that ASMase is required for autophagy suppression-
mediated ER stress. Hence, in the context of impaired autophagy,
due to the lack of ASMase, a defective onset of ER stress-induced
lipogenesis may be more signiﬁcant in the regulation of hepatic
steatosis than autophagy regulation by fat digestion. Overall,
these ﬁndings indicate that, while the impact of autophagy regu-
lation by ASMase in steatosis may be minor, ASMase-induced
autophagy activation may stand as a novel mechanism contribut-
ing to liver ﬁbrosis, based on the emerging link between autoph-
agy and HSC activation (see above).
ASMase regulates lysosomal membrane permeabilization
ASMase deﬁciency leads to lysosomal cholesterol accumulation
(LCA), as illustrated in macrophages from ASMase/ mice
[134]. As the primary phenotype of ASMase deﬁciency are
increased SM levels in lysosomes, the localization of cholesterol
in this compartment reﬂects the high afﬁnity of SM to bind cho-
lesterol, which decreases the efﬂux of cholesterol out of lyso-
somes [134]. Further, this trafﬁcking defect impairs the
esteriﬁcation of cholesterol by acyl-CoA:cholesterol acyltransfer-
ase, further contributing to LCA in ASMase/ macrophages. Inter-
estingly, enrichment of wild type macrophages with exogenous
SM reproduces LCA, due to decreased cholesterol efﬂux [134].
The characteristic LCA in ASMase/ cells is common to other
lysosomal storage diseases, such as NPC disease. In ﬁbroblasts
treatment with U18666A, which disrupts intracellular cholesterolJournal of Hepatology 201trafﬁcking and reproduces the NPC phenotype, induces LCA and
protects against LMP-mediated apoptosis [135]. Moreover,
NPC1/ Chinese hamster ovary cells are less sensitive to LMP
and staurosporine-induced apoptosis than wild type cells [135].
Hepatocytes from ASMase/ mice exhibit LCA, resulting in the
protection against amphiphilic lysosomotropic detergents, which
induce cell death and caspase activation following LMP [17]. As
LMP has been shown to contribute to PA-induced apoptosis
[51], ASMase/ hepatocytes are also resistant to PA-induced lipo-
toxicity, an effect that was reversed by depleting LCA with the
oxysterol 25-hydroxycholesterol [17]. Thus, LCA resulting from
ASMase deﬁciency modulates the autophagy-lysosomal degrada-
tion pathway and ameliorates LMP and the subsequent lipotoxic-
ity of saturated fatty acids. Overall, these ﬁndings indicate that
ASMase regulates ER stress, autophagy and LMP (Fig. 4), and spot-
light ASMase as an important player in lipid metabolism and
steatohepatitis.Interplay between methionine metabolism, acid
sphingomyelinase and phosphatidylcholine homeostasis
While disruption of the methionine cycle and PC depletion are
well documented in ASH/NASH, the interactions between these
metabolic perturbations and ASMase activation have been less
recognized.Mutual regulation between disruption of methionine metabolism
and ASMase activation
Ceramide C2 reduces the expression of liver MAT1A [136]. Fur-
ther, ASMase-induced ceramide generation mediates the down-
regulation of MAT1A mRNA expression and a decrease in MATI/
III protein levels induced by TNF, resulting in SAM depletion
and TNF-mediated liver failure [104]. Although ASMase triggers
the accumulation of glycosphingolipids, in particular ganglioside
GD3 as shown previously [14,106], the role of ASMase in silenc-
ing MAT1A was independent of glycosphingolipid generation.
Rather, ASMase-induced ceramide generation shortened the
half-life of MAT1A mRNA, in line with previous ﬁndings, showing
that ceramide C2 reduced the half-life of BCL2 mRNA through a
conserved AU-rich element in its 30 untranslated region, a mech-
anism whereby recruitment of the exosome by AU-binding pro-
teins affected 30-to-50 mRNA degradation [137,138]. Recent
ﬁndings showed the stabilization of MAT1A mRNA by AUF1 upon
its binding to AU-rich elements in the 30 untranslated region of
MAT1A [139]. However, it remains to be established whether
ASMase-induced ceramide generation interferes with AUF1 bind-
ing to destabilize MAT1A mRNA. Additionally, ﬁndings in mice,
fed a MCD diet, showed increased ceramide generation due to
selective ASMase activation [114]. The effect of MCD diet was
due to the lack of methionine but not choline in the diet, as these
effects were reproduced by feeding a MD but not a CD diet, and
were accompanied by increased Hcy and decreased SAM/SAH
[114]. Moreover, the increase in ceramide levels, caused by the
MCD diet, was independent of FAN [140], discarding a role for
NSMase activation in the generation of ceramide by MCD diet.
Thus, these results establish a self-sustained cycle in which dis-
ruption of the methionine cycle and ASMase activation engage
due to increased Hcy and lower SAM/SAH (Fig. 4).5 vol. 62 j 219–233 227
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Fig. 4. Central role of ASMase in the regulation ofMAT1A, PC homeostasis and lipid metabolism. Alterations in methionine metabolism, reﬂected as increased levels of
Hcy, decreased ratio of SAM/SAH, and ASMase activation engage in a feed forward loop via the ASMase-mediated reduction of MAT1A expression. ASMase-induced
generation of ceramide and sphingosine can inhibit the CDP-choline pathway of PC de novo biosynthesis, leading to decreased levels of PC. In addition, ASMase-mediated
SAM depletion could contribute to decreased phosphatidylethanolamine methylation, resulting in low PC generation. ASMase activation promotes autophagy and LMP and
is required for ER stress. While LMP contributes to lipotoxicity, the role autophagy in steatosis is controversial (dashed line). ER stress not only promotes lipogenesis and
fatty liver via activation of the SREBP transcription factors, but regulates expression of the mitochondrial transporting protein StARD1, which stimulates cholesterol
trafﬁcking to mitochondria, contributing to oxidative stress and hepatocellular manifestations of steatohepatitis.
ReviewA likely mechanism contributing to the relationship between
ASMase expression and decreased SAM levels is the methylation
status of ASMase in its CpG sites [100]. The epigenetic regulation
of ASMase by methylation has been shown in lymphoblasts from
patients with deﬁcient ASMase expression and upon incubation
with the demethylating agent 5-aza-20-deoxycytidine [141]. Con-
sistent with a role for SAM in regulating ASMase expression, liver
samples from 3-month-old MAT1A/ mice exhibit increased
basal expression and activity of ASMase, without changes in
NSMase or acid ceramidase (unpublished observations), which
preceded disease progression of MAT1A/ mice typically seen
at older age (8 months). ASMase activation in this model is
accompanied by the disruption of lipid metabolism and altera-
tions in DNA methylation, all of which could contribute to steato-
hepatitis progression of MAT1A/ mice. Wilson’s disease
provides another example of the potential interplay between
ASMase and SAM levels via DNA methylation. This autosomal
recessive genetic disorder is characterized by Cu2+ accumulation
in tissues, which manifests in neurological symptoms, anaemia
and liver disease. As mentioned above, Cu2+ activates ASMase
to cause erythrocyte and hepatocellular apoptosis that were pre-
vented by ASMase inhibition with desipramine [108]. Further,
Cu2+ binds noncompetitively to SAHH resulting in its inhibition
by releasing NAD+ [142] and altered methionine metabolism
has been described in Long-Evans Cinnamon rats, a model of
Wilson’s disease [143]. However, it remains to be established228 Journal of Hepatology 201whether altered DNA methylation in this model contributes to
ASMase activation and if ASMase inhibition by desipramine mod-
ulates methionine metabolism.
Besides methylation, ASMase is also subject to redox regula-
tion due to the presence of critical cysteine residues that regulate
its activity [100]. Hence, oxidative stress induced by alcohol or
HFD is a primary mechanism leading to ASMase activation. More-
over, as mentioned above, ASMase is activated by TNF, an impor-
tant player in steatohepatitis, in a cascade that involves the
proteolytic processing of pro-ASMase within TNF receptosomes
[144]. Thus, while ASMase activation and SAM depletion via
MAT1A silencing may engage in a vicious cycle, targeting SAM
depletion per se may not necessarily translate to the prevention
of ASMase activation, as other mechanisms can activate ASMase
independently of SAM depletion, such as inﬂammatory cytokines
(e.g. TNF) or oxidative stress.
ASMase regulates PC homeostasis
In addition to ASMase activation, MCD or MD diets deplete PC
levels (30–40%) and decrease PC/PE ratio in liver homogenates
and mitochondria [114]. Although the decrease in PC could be
the consequence of a reduced methylation of PE to PC by PEMT,
due to decreased SAM levels, it could also reﬂect the inhibition
of de novo PC synthesis by ceramide. For example, previous ﬁnd-
ings indicated that ceramide C2 or ceramide C6 directly inhibited5 vol. 62 j 219–233
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the CCT step of PC synthesis, resulting in increased phosphatidyl-
choline levels [145–147]. Moreover, it has been shown in vitro
that sphingosine inhibits CCT activity in rat liver [148]. As cera-
mide can be deacylated by ceramidases to sphingosine, it is con-
ceivable to imagine an inhibitory effect of ASMase on CCT by
ceramide as well as sphingosine generation (Fig. 4). Glucocorti-
coids increase PC levels by stimulating CCT activity, accounting
for the increase in surfactant synthesis in lung [149,150]. Inter-
estingly, betamethasone enhances CCT activity and PC levels in
rat lung, effects that were accompanied by increased SM content
and ASMase inhibition [151]. As described above, LCCTa/ mice
not only exhibit reduced hepatic PC and increased DAG levels, but
also display increased liver ceramide content [25]. Since strate-
gies that reversed PC levels or decreased DAG accumulation
(CDP-choline or lysophosphatidylcholine) in LCCTa/ mice fed
a HFD, failed to decrease ceramide content, this outcome suggests
that the source of ceramide generation in this model is not linked
to de novo SM synthesis in the Golgi (Fig. 3), indicating an alter-
native route for ceramide generation. Although the speciﬁc path-
way, contributing to the described increased hepatic ceramide
content in LCCTa/ mice, remains to be determined, an attractive
possibility would be the activation of ASMase, establishing a link
between low PC and ASMase activation. Accordingly, ASMase/
mice exhibit increased PC levels in the liver and brain [102],
which contribute to the protection of ASMase/ mice against
MCD-induced hepatic steatosis [17]. Although further work is
needed to characterize the functional relationship between
ASMase and PC, it appears that PC reduction and ASMase
activation engage in a vicious cycle of potential signiﬁcance in
steatohepatitis.Future perspectives
The lack of approved therapies contributes to the growing num-
ber of patients who will face ASH/NASH and progressive liver
dysfunction in the near future. Disturbed methionine metabolism
is a key hallmark of ASH/NASH, and alterations in PC homeostasis
contribute to disease progression. Targeting these speciﬁc path-
ways with exogenous SAM, betaine or replenishment of PC levels
has shown promising results in experimental models
[20,25,31,152,153]. However, while SAM treatment has shown
beneﬁcial effects in patients with moderate alcoholic cirrhosis
[24,154], the impact of betaine or polyenylphosphatidylcholine
in patients with NASH has been less promising [21,26]. Choline
supplementation protected Pemt//Ldlr/ mice against high
fat high cholesterol diet induced steatohepatitis. However, pro-
tection was not due to restoration of hepatic PC levels or PC/PE
ratio but was associated with decreased hepatic cholesterol accu-
mulation and normalization of the expression of cholesterol-
metabolizing enzymes [155]. Moreover, complex diseases, such
as steatohepatitis, require combination therapies and the elucida-
tion of interplays of metabolic pathways individually recognized
to play a role in this process may open new therapeutic avenues.
In this scenario, decreased SAM content by reduced MAT1A
expression and low PC levels activate ASMase, which in turn,
represses MAT1A and impairs PC de novo biosynthesis, establish-
ing a feed-forward loop. Moreover, ASMase is required for the
activation of pathways that regulate steatosis, ﬁbrosis and lipo-
toxicity. This emerging functional link provides a rationale to
restore SAM and PC levels in combination with ASMase inhibitionJournal of Hepatology 201that may be of potential relevance in ASH/NASH treatment.
Moreover, in addition to the contribution of SAM/PC depletion
to ASMase activation, ASMase becomes activated in response to
other stimuli, including inﬂammatory cytokines (e.g. TNF) or oxi-
dative stress, which are known key players in steatohepatitis.
While further work remains to be done as to whether ASMase
activation precedes the depletion of SAM/PC or not, both pro-
cesses are mutually regulated in a vicious cycle of potential rele-
vance to chronic liver disease. Targeting just SAM/PC may not
guarantee ASMase inactivation. Although a new generation of
ASMase inhibitors are being developed, tricyclic antidepressants,
which are already in the clinic, have been shown to efﬁciently
antagonize ASMase by preventing its proteolytic activation. Thus,
it may be constructive to test these in new experimental models
that combine alterations in SAM/SAH or decreased PC levels with
ASMase deﬁciency to more accurately evaluate the potential of
applying this approach to patients.Financial support
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